Krsnaa Diagnostics Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 2 per equity share.

Profit growth above 25%EBITDA margin expansionContingent liabilities increasedDebt to equity above the thresholdEmphasis of matterResults View source PDF Explain this filing

KRSNAA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹550.00

prior close

₹622.55

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.7%-2.2% vs market

Healthcare Service Provider peers, median of 24sector-1.3%-0.1% vs sector

On the reaction day the stock moved 2.2 pts less than Nifty Microcap 250 and 0.1 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-7.9

10m

-9.7

15m

-8.8

30m

-8.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5+0.7-2.2-1.3-0.1

Next day

-1.8+0.7-2.5+1.3-3.1

+0.0+0.0-0.0+1.2-1.2

-1.7-1.1-0.6-1.3-0.4

-0.5+0.0-0.5-1.2+0.7

-1.7+0.3-1.9-0.8-0.9

+0.5+1.1-0.6-1.3+1.8

15d

-2.5+4.9-7.4+1.6-4.2

-1.8+5.3-7.1-0.1-1.7

-1.4+6.9-8.3-4.2+2.8

+1.9+11.9-10.0+0.8+1.1

UpDownMarket · Nifty Microcap 250Sector · Healthcare Service Provider peers, median of 24Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Krsnaa Diagnostics reported audited standalone PAT of Rs. 1,026.75 million (up ~24%) and consolidated PAT of Rs. 1,014.31 million (up ~30.7%) for FY 2025-26. Standalone revenue was Rs. 6,909.47 million (flat YoY at +1.4%), while consolidated revenue rose 7.8% to Rs. 7,727.74 million. EBITDA margins expanded by ~3.1 percentage points YoY to ~32% on standalone basis. The Board recommended a final dividend of Rs. 2 per share (40% face value), subject to shareholder approval. Key risk noted: Income Tax authorities raised a total demand of Rs. 626.90 million across multiple assessment years (AY 2017-18 to AY 2019-20) for alleged undisclosed income and disallowed deductions. The Company has filed appeals and deposited Rs. 102.77 million under protest. Statutory auditors issued an unmodified opinion with an Emphasis of Matter on the tax matter. Borrowings surged significantly (non-current borrowings jumped from Rs. 185 million to Rs. 4,371 million), partly due to debenture issuance of Rs. 4,174 million. A fair value gain of Rs. 258.75 million was recognized on derecognition of associate Apulki Healthcare. New statutory auditor M/s Kirtane & Pandit LLP appointed for FY 2026-27 to 2030-31.

Likely market impact

The company delivered strong PAT growth (~30%) and margin expansion, with an unmodified audit opinion providing comfort. However, the Rs. 626.90 million tax demand remains a contingent liability risk, and the large increase in borrowings raises leverage concerns. The dividend is positive for shareholder returns.